Charles R Harrington
Overview
Explore the profile of Charles R Harrington including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
65
Citations
1334
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Santos R, Lee S, Lofthouse R, Melis V, Robinson L, Leith M, et al.
FEBS J
. 2025 Feb;
PMID: 39960781
Tauopathies are a heterogeneous mixture of neurodegenerative disorders, including Alzheimer's disease and frontotemporal dementia (FTD), characterised by the accumulation of tau filaments in brain tissue. Tau protein aggregation is inhibited...
2.
Schwab K, Robinson L, Annschuetz A, Dreesen E, Magbagbeolu M, Melis V, et al.
Brain Res Bull
. 2024 Dec;
220():111172.
PMID: 39694148
The negative interference of treatments between the acetylcholinesterase inhibitor rivastigmine and the tau aggregation inhibitor hydromethylthionine mesylate (HMTM) has been reported in Line 1 tau-transgenic mice, which overexpress a truncated...
3.
Arastoo M, Penny L, Lofthouse R, Abdallah A, Abrahamsson A, Marini P, et al.
Alzheimers Res Ther
. 2024 Oct;
16(1):209.
PMID: 39358820
Background: Recent advances in blood-based biomarker discovery are paving the way for simpler, more accessible diagnostic tools that can detect early signs of Alzheimer's disease (AD). Recent successes in the...
4.
Cranston A, Kraev I, Stewart M, Horsley D, Santos R, Robinson L, et al.
Cell Signal
. 2024 Jun;
121:111269.
PMID: 38909930
Glutamatergic neurotransmission, important for learning and memory, is disrupted in different ways in patients with Alzheimer's disease (AD) and frontotemporal dementia (FTD) tauopathies. We have previously reported that two tau...
5.
Penny L, Lofthouse R, Arastoo M, Porter A, Palliyil S, Harrington C, et al.
Transl Neurodegener
. 2024 May;
13(1):25.
PMID: 38773569
The use of biomarker-led clinical trial designs has been transformative for investigating amyloid-targeting therapies for Alzheimer's disease (AD). The designs have ensured the correct selection of patients on these trials,...
6.
Schwab K, Lauer D, Magbagbeolu M, Theuring F, Gasiorowska A, Zadrozny M, et al.
Brain Res Bull
. 2024 Apr;
212:110955.
PMID: 38677558
In clinical trials for Alzheimer's disease (AD), hydromethylthionine mesylate (HMTM) showed reduced efficacy when administered as an add-on to symptomatic treatments, while it produced a significant improvement of cognitive function...
7.
Zadrozny M, Drapich P, Gasiorowska-Bien A, Niewiadomski W, Harrington C, Wischik C, et al.
Cells
. 2024 Apr;
13(7.
PMID: 38607082
Basal forebrain cholinergic dysfunction, most likely linked with tau protein aggregation, is a characteristic feature of Alzheimer's disease (AD). Recent evidence suggests that tau protein is a putative target for...
8.
Horsley D, Rickard J, Vorley T, Leeper M, Wischik C, Harrington C
Methods Mol Biol
. 2024 Mar;
2754:93-104.
PMID: 38512662
Aggregation of tau protein is a pathological hallmark of Alzheimer's disease and other neurodegenerative tauopathies. Inhibition of tau aggregation may provide a method for treatment of these disorders. Methods to...
9.
Schwab K, Frahm S, Magbagbeolu M, Horsley D, Goatman E, Melis V, et al.
Eur J Pharmacol
. 2024 Mar;
970:176505.
PMID: 38503400
Alpha-Synuclein (α-Syn) aggregation is a pathological feature of synucleinopathies, neurodegenerative disorders that include Parkinson's disease (PD). Here, we explored the efficacy of N,N,N',N'-tetraethyl-10H-phenothiazine-3,7-diamine dihydrochloride (LETC), a protein aggregation inhibitor, on...
10.
Schwab K, Magbagbeolu M, Theuring F, Harrington C, Wischik C, Riedel G
Sci Rep
. 2024 Mar;
14(1):6239.
PMID: 38486089
The accumulation of α-synuclein (α-Syn) into Lewy bodies is a hallmark of synucleinopathies, a group of neurological disorders that include Parkinson's disease (PD) and dementia with Lewy bodies (DLB). Small...